fjrigjwwe9r0Board:Content
Intriguing data are now emerging from a new patented blend of PMFs and tocotrienols called SytrinolTM. Three human clinical studies investigating the effect of Sytrinol on blood lipids have yielded impressive results. In the first study, 10 subjects having an average total cholesterol >230 mg/dl, LDL-cholesterol > 155 mg/dl and total triglycerides of between 100 and 307 mg/dl received 300 mg of Sytrinol for 4 weeks. Compared with baseline values, total cholesterol decreased by 24%, LDL-cholesterol decreased by 19% and triglycerides dropped by 24%. These results were confirmed in a second study also involving 10 hypercholesterolemic subjects in whom similar reductions in lipid parameters were observed. A 21% reduction in apo B levels was also observed in this study, supporting the notion that polymethoxylated flavones inhibit apo B secretion. Given the success of the first two studies, a placebo-controlled, randomized, 3-phase, cross-over study involving 120 hypercholesterolemic subjects was initiated. During phase one subjects received either 300 mg/day of Sytrinol or a placebo for 12 weeks. Blood was drawn at baseline, 4, 8 and 12 weeks. The second phase of the study consisted of a 4 week washout period, followed by phase 3 in which the subjects were crossed over, so that those that received the placebo in phase 1 would then receive the active treatment. After 12 weeks, compared with baseline values, subjects receiving Sytrinol experienced statistically significant average reductions for total cholesterol, LDL-cholesterol and triglycerides of 27, 25, and 30%, respectively. No significant changes were reported in the placebo group. HDL-cholesterol was not significantly altered in either group. As of the time of this publication, the data from the first two human trials have been submitted for publication, and the third trial is now in its third phase. In all 3 studies, Sytrinol was well tolerated and there were no differences in adverse effects between the treatment and placebo groups. The strength of these results may be attributable to the unique combination of mechanisms of action by which Sytrinol is thought to work; inhibition of apo B secretion, inhibition of triglyceride synthesis, and inhibition of cholesterol synthesis |